SCHEMBL1178232

SCHEMBL1178232

O=C(NS(=O)(=O)c1ccccc1)c1ccc2nc(Cc3ccccc3)n(Cc3ccc(Cl)cc3Cl)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.53
TP53 P04637 2/20 0.49
MAPT P10636 1/20 0.49
POLB P06746 1/20 0.47
FLT1 P17948 5/20 0.47
FLT4 P35916 5/20 0.47
KDR P35968 5/20 0.47
LMNA P02545 2/20 0.46
GNRHR P30968 1/20 0.45
DRD2 P14416 1/20 0.45
TBXA2R P21731 1/20 0.45
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA13 Q8N1Q1 1/20 0.43
VDR P11473 1/20 0.43
CCR2 P41597 1/20 0.42
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1160435 0.93 GNRHR (0.51) PPARGTP53MAPTPOLBFLT1
SCHEMBL1160351 0.93 TP53 (0.51) PPARGTP53POLBLMNADRD2
SCHEMBL1160394 0.87 PPARG (0.70) PPARGFLT1FLT4KDRLMNA
Hydrochloric Acid SCHEMBL6171221 0.86 PPARG (0.69) PPARGFLT1FLT4KDRLMNA
SCHEMBL1160318 0.86 TP53 (0.51) PPARGTP53LMNADRD2TBXA2R
SCHEMBL6169301 0.85 TP53 (0.52) PPARGTP53MAPTPOLBLMNA
SCHEMBL1160437 0.83 FLT1 (0.50) PPARGTP53MAPTPOLBFLT1
SCHEMBL6171260 0.80 DRD2 (0.52) PPARGTP53MAPTPOLBLMNA
SCHEMBL6134973 0.80 PPARG (0.70) PPARGFLT1FLT4KDRLMNA
SCHEMBL6304196 0.79 PPARG (0.67) PPARGFLT1FLT4KDRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140024692-A1 Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma AESTUS THERAPEUTICS, INC. (US) 2014-01-23 US disclosed
US-8563589-B2 Methods of treating neuropathic pain with benzimidazole derivative agonists of PPARgamma SAMEEVE CORP 2013-10-22 US disclosed
US-20110028527-A1 Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma AESTUS THERAPEUTICS, INC. (US) 2011-02-03 US disclosed
EP-0882718-B1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-08-31 EP disclosed
US-6352985-B1 CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-05 US disclosed
US-6166219-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-12-26 US disclosed
EP-0882718-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024692-A1 Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma PPARG, PPARA, PPARD PPARG 1/4885TP53 2963/4885MAPT 4356/4885
US-20110028527-A1 Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma PPARG, PPARA, PPARD PPARG 1/4885TP53 2963/4885MAPT 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.